STAGE III RENAL CELL CANCER AJCC V8
Clinical trials for STAGE III RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of a combination of two or three drugs (cabozantinib, nivolumab, and possibly ipilimumab) in people with advanced genitourinary cancers that have spread. About 152 adults with these cancers will participate. The goal is to fin…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:25 UTC
-
Targeted drug shows promise for Gene-Deficient cancers
Disease control OngoingThis study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack a working SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The main goal is to see if the tumors shrink or stop growing.
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:24 UTC
-
Promising drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for kidney cancer patients: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study compares two treatment options for people with advanced kidney cancer that has spread and worsened after prior immunotherapy. About 90 participants will receive either a combination of two drugs (lenvatinib and everolimus) or a single drug (cabozantinib). The goal is t…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a superfruit boost immunotherapy for kidney cancer?
Disease control OngoingThis early-phase trial tests adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) for people with advanced kidney cancer that has spread. The main goal is to find the safest dose and see how it affects gut bacteria. About 31 participants will …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Gut bacteria boosts cancer therapy? new combo trial for kidney cancer
Disease control OngoingThis early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard cancer drugs (nivolumab and cabozantinib) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement alongside their regular th…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other parts of the body. About 18 participants will receive the combination for 12 weeks before their operat…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug shrinks kidney tumors before surgery in early trial
Disease control OngoingThis study tests whether the drug cabozantinib can shrink kidney tumors before surgery in people with locally advanced clear cell renal cell carcinoma. About 22 participants will receive cabozantinib before their operation. The goal is to see if the drug reduces tumor size and he…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo therapy shows promise in advanced kidney cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with untreated, metastatic clear cell renal cell carcinoma are participating. Th…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New immune cell therapy targets five Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 05, 2026 11:53 UTC